Drug Trial Radar · NCT05158491
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
Last checked: Nov 20, 2026Latest source record: Jan 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
63
Planned (sponsor's estimate)
Start
Nov 11, 2021
Primary completion
Dec 31, 2022
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- JenKem Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University Cancer Hospital & Institute
- First posted
- Dec 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)
Conditions
- Small Cell Lung Cancer (SCLC)
Interventions
JK-1201IDrug
JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine dose limited toxicity (DLT) of JK-1201I in patients with SCLC.Time frame: 21days
- To determine the maximum tolerance dose level of JK-1201I in patients with SCLC.Time frame: 21days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.